203 related articles for article (PubMed ID: 36944944)
21. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
[TBL] [Abstract][Full Text] [Related]
22. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy.
Chen K; Ma Y; Liu X; Zhong X; Long D; Tian X; Zheng L; Yang Y
Cancer Lett; 2023 Nov; 576():216421. PubMed ID: 37778681
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets.
Chen K; Liu X; Liu W; Wang F; Tian X; Yang Y
Hum Mol Genet; 2022 May; 31(10):1705-1719. PubMed ID: 34957503
[TBL] [Abstract][Full Text] [Related]
24. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
25. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Yu S; Lu Z; Chen J
Front Immunol; 2022; 13():1027459. PubMed ID: 36325339
[TBL] [Abstract][Full Text] [Related]
27. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
28. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma.
Loch FN; Kamphues C; Beyer K; Schineis C; Rayya W; Lauscher JC; Horst D; Dragomir MP; Schallenberg S
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768480
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
30. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
[TBL] [Abstract][Full Text] [Related]
31. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
32. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
[TBL] [Abstract][Full Text] [Related]
33. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.
Zhou Y; Jin X; Yu H; Qin G; Pan P; Zhao J; Chen T; Liang X; Sun Y; Wang B; Ren D; Zhu S; Wu H
Theranostics; 2022; 12(5):2080-2094. PubMed ID: 35265200
[No Abstract] [Full Text] [Related]
34. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
[TBL] [Abstract][Full Text] [Related]
35. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
Hrudka J; Lawrie K; Waldauf P; Ciprová V; Moravcová J; Matěj R
Virchows Arch; 2020 Nov; 477(5):687-696. PubMed ID: 32424767
[TBL] [Abstract][Full Text] [Related]
36. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
37. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
38. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
39. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
[TBL] [Abstract][Full Text] [Related]
40. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
